| itacitinib (INCB039110) / Incyte |
NCT02456675: INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma |
|
|
| Terminated | 2 | 8 | NA | INCB040093 Monotherapy, INCB040093, itacitinib, INCB039110 | Incyte Corporation | Refractory Hodgkin Lymphoma, Recurrent Adult Hodgkin's Lymphoma | 12/16 | 12/16 | | |
NCT05757219: Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy |
|
|
| Recruiting | 2 | 27 | US | Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy, YESCARTA, Axi-cel | H. Lee Moffitt Cancer Center and Research Institute, Incyte Corporation | Diffuse Large B Cell Lymphoma | 10/24 | 11/26 | | |
NCT02760485 / 2017-002773-19: A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Completed | 1/2 | 33 | US | itacitinib, INCB039110, ibrutinib | Incyte Corporation | Lymphoma | 06/22 | 06/22 | | |
| Active, not recruiting | 1/2 | 23 | US | Itacitinib, INCB039110, Everolimus, Afinitor | University of Pennsylvania | Classical Hodgkin Lymphoma | 10/24 | 06/27 | | |
